Rabbit Anti-Human CDK14 Polyclonal antibody

Recent reports have indicated a high frequency of deletions of MTS1 (CDKN2, p16(ink4), CDK14) in acute lymphoblastic leukaemias (Ws). This gene is located at. chromosome 9p21 and encodes an inhibitor of cyclin D-dependent kinases. In contrast with the observations in some other malignancies, no inactivation of MTS1 by intragenic mutation was demonstrated in leukaemias. A contribution of MTS1 alterations to leukaemogenesis therefore remains questionable. In order to test for the implication of MTS1 as a tumour suppressor gene in paediatric ALLs we have explored the 9p21 chromosomal region in 46 children with this disease. The copy number of the MTS1 gene in blasts from the patients was determined using a quantitative PCR assay enabling us to precisely detect mono- and bi-allelic deletions. Rearrangements of the gene were sought by Southern blot analysis. The extent of the deletions was studied using microsatellite markers spanning the 9p21 chromosomal region. Point mutations were sought in exon 1 and exon 2 of the MTS1 gene in patients with a mono-allelic deletion. In addition, exon 2 of MTS1, which contains two-thirds of the coding region, was sequenced in all patients who had no deletion of the gene. Altogether, our data are consistent with the view that MTS1 is the target of 9p21 deletions. Either one or two alleles of the gene were deleted in 36% of nonselected children with B-lineage ALL and both alleles were deleted in all seven patients we studied with T-lineage ALL. The absence of any point mutation implies that the major mechanism of inactivation of MTS1 in ALLs is deletional.

The critical roles for long non-coding RNAs (lncRNAs) have been demonstrated for series of cancers, including osteosarcoma. Nevertheless, the accurate mechanism of lncRNAs in osteosarcoma is elusive. In this assay, mechanical researches are performed to investigate the effect and mechanism of 1ncRNA OIP5-AS1 in osteosarcoma tumorigenesis. Results revealed that OIP5-AS1 level was elevated in osteosarcoma tissue and cells. Clinically, OIP5-AS1 high-expression was closely correlated with osteosarcoma patients' poor prognosis. Mechanistically, silenced OIP5-AS1 expression significantly repressed the proliferative ability and accelerated the apoptosis, meanwhile triggered G0/G1 phase cycle arrest in vitro and mice neoplasm growth in vivo. Subsequently, miR-223 was predicted to target the 3'-UTR of OIP5-AS1 and constituted RNA induced silencing complex, which was confirmed by RNA immunoprecipitation and luciferase reporter assay. Besides, miR-223 targeted the CDK14 mRNA 3'-UTR. In conclusion, our study found the critical regulation of OIP5-AS1/miR-223/CDK14 axis on osteosarcoma tumorigenesis, indicating the tumor promoting role of OIP5-AS1 for osteosarcoma.